Holen Sie sich die Stockscreener-App
21.28
0.61%
0.1078
Schlusskurs vom Vortag:
$21.17
Offen:
$21.32
24-Stunden-Volumen:
368.15K
Relative Volume:
1.34
Marktkapitalisierung:
$2.76B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+8.56%
1M Leistung:
-5.21%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$20.92
$21.82
1-Wochen-Bereich:
$19.58
$21.82
52-Wochen-Spanne:
$19.01
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Firmenname
Kailera Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare KLRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
21.32 | 2.74B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
436.53 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.05 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.75 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.32 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.77 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Aktie (KLRA) Neueste Nachrichten
Meet the new IPO trying to take on Eli Lilly and Novo Nordisk in obesity - MSN
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Kailera Therapeutics (KLRA) Insider Trading Activity 2026 $KLRA - MarketBeat
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
This weight-loss drug challenger could follow Eli Lilly's playbook: Analyst - MSN
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? - AOL.com
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
Kailera Therapeutics IPO: Competing with Eli Lilly and Novo Nordisk in GLP-1 Weight LossNews and Statistics - IndexBox
Is Kailera Therapeutics a Buy After Its Sizzling IPO? - The Motley Fool
Is Kailera Therapeutics a Buy After Its Sizzling IPO? - The Motley Fool
How AI is Transforming Health Literacy and Engagement - William Blair
RTW Bio NAV Rises 7.0% In April As Biotech IPO And M&A Activity Accelerates - DirectorsTalk Interviews
Evercore Initiates Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
TD Cowen Initiates Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo
Kailera Therapeutics, Inc. (KLRA) Total Expenses (TTM) - Zacks Investment Research
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst - Yahoo Finance
Kailera Therapeutics, Inc. (KLRA) Profit Margin (Quarterly) - Zacks Investment Research
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions - ChartMill
Kailera Therapeutics, Inc. (KLRA) Dividend Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Market Cap - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Book Value (Per Share) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Net Income (Quarterly) - Zacks Investment Research
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity - Investor's Business Daily
Kailera's record IPO headlines strong April for biopharma financings - BioWorld News
A Quick Look at Today's Ratings for Kailera Therapeutics(KLRA.US), With a Forecast Between $30 to $48 - Moomoo
Kailera Therapeutics (KLRA) Stock Forecast and Price Target 2026 $KLRA - MarketBeat
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target - marketscreener.com
Leerink Initiates Kailera Therapeutics at Outperform With $36 Price Target - marketscreener.com
Evercore ISI Kailera Therapeutics Initiates at Outperform - Moomoo
William Blair Initiates Kailera Therapeutics at Outperform - Moomoo
Investment bank Leerink Partners announces the initiation of research coverage on biopharmaceutical company Kailera Therapeutics. - Bitget
TD Cowen initiates Kailera stock with buy on weight loss drug potential - Investing.com Canada
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
William Blair initiates Kailera stock with Outperform rating By Investing.com - Investing.com Canada
JPMorgan initiates Kailera stock at Overweight on obesity pipeline By Investing.com - Investing.com Canada
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Dividend (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Free Cash Flow (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Total Long Term Debt (Quarterly) - Zacks Investment Research
Odyssey raises $304 million in upsized Nasdaq debut - The Pharma Letter
Kailera Therapeutics, Inc. (KLRA) Price To Free Cash Flow - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Gross Profit (TTM) - Zacks Investment Research
KLRA: Kailera Therapeutics, Inc.12 Month EPS - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Earnings Yield (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Return On Equity (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
KLRA : Kailera Therapeutics, Inc. Key Company Details - Zacks Investment Research
Finanzdaten der Kailera Therapeutics Inc-Aktie (KLRA)
Es liegen keine Finanzdaten für Kailera Therapeutics Inc (KLRA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Kailera Therapeutics Inc-Aktie (KLRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):